CELF1 and myotonic dystrophy type 1: Therefore, posttranscriptional modifications of CELF1 UTR sequences contribute to CELF1 activity under physiological and pathological conditions such as DM1, and modulation of alternative splicing of CELF1 can be considered as a potential therapeutic strategy.